Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Book Chapters
, 2018, 'Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists' Collaboration', in Hypertension A Companion to Braunwald S Heart Disease, pp. 433 - 441, http://dx.doi.org/10.1016/B978-0-323-42973-3.00047-0
, 2018, '47 Meta-Analyses of Blood Pressure Lowering Trials and the Blood Pressure Lowering Treatment Trialists’ Collaboration', in Hypertension: A Companion to Braunwald's Heart Disease, Elsevier, pp. 433 - 441, http://dx.doi.org/10.1016/b978-0-323-42973-3.00047-0
, 2015, 'Fibrates: risk-benefits and role in treating dyslipidemias', in Dyslipidemias Pathophysiology, Evaluation and Management, Humana Press
, 2014, 'Kidney Disease in Diabetes', in Managing Cardiovascular Complications in Diabetes, pp. 58 - 86, http://dx.doi.org/10.1002/9781118337967.ch3
, 2014, 'kidney disease in diabetes', in Managing Cardiovascular Complications in Diabetes, John Wiley & Sons
, 2012, 'Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease', in Wang Y (ed.), Cochrane Database of Systematic Reviews, Wiley, http://dx.doi.org/10.1002/14651858.cd009631
, 2011, 'Interventions for preventing intradialytic hypotension in haemodialysis patients', in Gangadharan Komala M (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd009459
, 2011, 'Intensive glycemic control and renal outcome', in Diabetes and the Kidney, Karger Medical and Scientific Publishers
, 2010, 'Antiplatelet agents for chronic kidney disease', in Palmer SC (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd008834
, 2010, 'Interventions for erythropoietin‐resistant anaemia in dialysis patients', in Badve SV (ed.), Cochrane Database of Systematic Reviews, Wiley, http://dx.doi.org/10.1002/14651858.cd006861.pub2
, 2009, 'Antioxidants for chronic kidney disease', in Perkovic V (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd008176
, 2009, 'Lipid lowering in chronic kidney disease', in Therapeutic Strategies in Lipid Disorders
, 2004, 'HMG CoA reductase inhibitors (statins) for kidney transplant recipients', in Perkovic V (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd005019
Journal articles
, 2026, 'Randomized Clinical Trials of Deutaleglitazar in Healthy Participants and in Patients with Diabetic Kidney Disease', Kidney International Reports, 11, http://dx.doi.org/10.1016/j.ekir.2026.107037
, 2026, 'Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis', Lancet Diabetes and Endocrinology, 14, pp. 818 - 830, http://dx.doi.org/10.1016/S2213-8587(26)00134-8
, 2026, 'Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial', Nephrology Dialysis Transplantation, pp. gfag203, http://dx.doi.org/10.1093/ndt/gfag203
, 2026, 'Finerenone in Persons with Chronic Kidney Disease without Diabetes', New England Journal of Medicine, 395, pp. 533 - 545, http://dx.doi.org/10.1056/NEJMoa2604625
, 2026, 'Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy on CKD progression', Nephrology Dialysis Transplantation, pp. gfag172, http://dx.doi.org/10.1093/ndt/gfag172
, 2026, 'Hematuria Remission and Prognosis in IgA Nephropathy: A Post Hoc Analysis of the TESTING Randomized Clinical Trial', American Journal of Kidney Diseases, 88, pp. 278 - 281, http://dx.doi.org/10.1053/j.ajkd.2026.02.649
, 2026, 'Sodium-glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes and Chronic Kidney Disease Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20 mL/min/1.73 m2', Journal of Cardiac Failure, 32, pp. 1408 - 1417, http://dx.doi.org/10.1016/j.cardfail.2026.01.020
, 2026, 'Iptacopan in IgA Nephropathy - Final 24-Month Data', New England Journal of Medicine, 395, pp. 465 - 477, http://dx.doi.org/10.1056/NEJMoa2600743
, 2026, 'Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial', JAMA, 336, pp. 296 - 305, http://dx.doi.org/10.1001/jama.2026.9379
, 2026, 'Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial', JAMA, 336, pp. 224 - 235, http://dx.doi.org/10.1001/jama.2026.9923
, 2026, 'Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals', Nature Medicine, 32, pp. 2629 - 2638, http://dx.doi.org/10.1038/s41591-026-04437-z
, 2026, 'Sex disparities in receiving evidence-based medications in patients with CKD', Nephrology Dialysis Transplantation, pp. gfag135, http://dx.doi.org/10.1093/ndt/gfag135
, 2026, 'Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)', Lancet, 407, pp. 2375 - 2386, http://dx.doi.org/10.1016/S0140-6736(26)01009-3
, 2026, 'Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease', Journal of the American College of Cardiology, 87, pp. 2996 - 3012, http://dx.doi.org/10.1016/j.jacc.2026.02.5125
, 2026, 'Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials', American Journal of Preventive Cardiology, 27, http://dx.doi.org/10.1016/j.ajpc.2026.101642
, 2026, 'Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial', Diabetes Care, 49, pp. e92 - e93, http://dx.doi.org/10.2337/dc26-0466
, 2026, 'Iron deficiency and risk of cardiovascular events in CKD: insights from the ASCEND-ND trial', European Journal of Heart Failure, pp. xuag171, http://dx.doi.org/10.1093/ejhf/xuag171
, 2026, 'Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial', New England Journal of Medicine, 394, pp. 1916 - 1924, http://dx.doi.org/10.1056/NEJMoa2514415
, 2026, 'The authors reply', Kidney International, 109, pp. 1036 - 1037, http://dx.doi.org/10.1016/j.kint.2026.01.027
, 2026, 'A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy', Kidney International, 109, pp. 738 - 749, http://dx.doi.org/10.1016/j.kint.2025.12.024
, 2026, 'When “Low-Grade” Is No Longer Low Risk in IgA Nephropathy', Clinical Journal of the American Society of Nephrology, Publish Ahead of Print, http://dx.doi.org/10.2215/CJN.0000001044
, 2026, 'Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis', European Heart Journal, 47, pp. 1649 - 1657, http://dx.doi.org/10.1093/eurheartj/ehaf962
, 2026, 'Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial', New England Journal of Medicine, 394, pp. 635 - 646, http://dx.doi.org/10.1056/NEJMoa2512133
, 2026, 'Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis', JAMA, 335, pp. 220 - 232, http://dx.doi.org/10.1001/jama.2025.20835
, 2026, 'SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis', JAMA, 335, pp. 233 - 244, http://dx.doi.org/10.1001/jama.2025.20834
, 2026, 'Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction', JAMA Cardiology, 11, pp. 89 - 97, http://dx.doi.org/10.1001/jamacardio.2025.4491
, 2026, 'A meta-analysis of albuminuria as a surrogate endpoint for kidney failure', Nature Medicine, 32, pp. 281 - 287, http://dx.doi.org/10.1038/s41591-025-04057-z
, 2026, 'Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level Pooled Analysis from the CANVAS Program and CREDENCE Trial', Journal of Cardiac Failure, 32, pp. 151 - 156, http://dx.doi.org/10.1016/j.cardfail.2025.05.021
, 2026, 'Cardiac impact of dapagliflozin in advanced chronic kidney disease: rationale and design of the Renal Lifecycle Trial cardiac imaging sub-studies', Clinical Kidney Journal, 19, http://dx.doi.org/10.1093/ckj/sfaf376
, 2026, 'From progression to remission: a new paradigm for success in chronic kidney disease', Kidney International, 109, pp. 17 - 21, http://dx.doi.org/10.1016/j.kint.2025.10.004
, 2026, 'Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes', Nature Reviews Nephrology, http://dx.doi.org/10.1038/s41581-026-01117-6
, 2026, 'International Society of Nephrology International Expert Forum: Exploring the Nexus of Cardiovascular-Kidney-Metabolic Health', Kidney International, http://dx.doi.org/10.1016/j.kint.2026.06.044
, 2026, 'Iptacopan in Patients With IgA Nephropathy From East Asia', Kidney International Reports, 11, pp. 117 - 128, http://dx.doi.org/10.1016/j.ekir.2025.10.017
, 2026, 'Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial', Clinical Journal of the American Society of Nephrology, Publish Ahead of Print, http://dx.doi.org/10.2215/CJN.0000000974
, 2026, 'Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial', American Journal of Nephrology, pp. 1 - 11, http://dx.doi.org/10.1159/000550796
, 2026, 'Predictive Value of the Oxford Classification for the Effect of Glucocorticoid Therapy in IgA Nephropathy', Journal of the American Society of Nephrology, 37, pp. 150 - 159, http://dx.doi.org/10.1681/ASN.0000000796
, 2026, 'The Role of Inflammation and High-Sensitivity C-Reactive Protein in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The FLAME-ASCVD Survey among Nephrologists', Cardiorenal Medicine, pp. 14 - 24, http://dx.doi.org/10.1159/000550094